Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: Systematic review and decision-analytical modelling

Health Technology Assessment

Volumn 9, Issue 27, 2005, Pages

  Robinson, M ^a   Palmer, S ^b   Sculpher, M ^b   Philips, Z ^b   Ginnelly, L ^b   Bowens, A ^a   Golder, S ^c   Alfakih, K ^d   Bakhai, A ^e   Packham, C ^f   Cooper, N ^g   Abrams, K ^g   Eastwood, A ^c   Pearman, A ^a   Flather, M ^e   Gray, D ^h   Hall, A ^d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; OMEPRAZOLE; OXYGEN; PLACEBO; TICLOPIDINE; TIROFIBAN; TROPONIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOGEN RECEPTOR;

ACUTE DISEASE; AGE; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIABETES MELLITUS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG USE; EVIDENCE BASED MEDICINE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; INFORMATION PROCESSING; MEDICAL DECISION MAKING; MEDICAL PRACTICE; META ANALYSIS; NEUTROPENIA; PATIENT CARE; PRACTICE GUIDELINE; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; ST SEGMENT DEPRESSION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG ANTAGONISM; DRUG COMBINATION; ECONOMICS; HEART INFARCTION; RISK ASSESSMENT; SYNDROME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANGINA, UNSTABLE; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SYNDROME;

EID: 24944550152     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta9270     Document Type: Review

References (111)

1. Gersh BJ. Current issues in reperfusion therapy. Am J Cardiol 1998;82:3-11.
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000;102:1193-209.
3. Purcell H. The epidemiology of unstable angina. Br J Cardiol 1998;5:S3-4.
4. Braunwald E. Unstable angina: an etiologic approach to management. Circulation 1998; 98:2219-22.
5. Klootwijk P, Meij S, Melkert R, Lenderink T, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation 1998;98:1358-64.
6. Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36:685-92.
7. Department of Health. Hospital Episode Statistics. Finished consultant episodes by diagnosis and operative procedure; injury/poisoning by external causes. England: financial year 1995-96. London: Department of Health; 1997.
8. British Cardiovascular Intervention Society. BCIS Audit Returns of Interventional Procedures 2000. London: British Cardiovascular Intervention Society; 2001.
9. McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess 2000; 4(30):1-95.
10. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338:1498-505.
11. PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.
12. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
13. Collinson J, Flather M, Fox K, Findlay I, Rodrigues E, Dooley P, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000;21:1450-7.
14. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian lamifiban study. Circulation 1996;94:899-905.
15. Katz DA, Griffith JL, Beshansky JR, Selker HP. The use of empiric clinical data in the evaluation of practice guidelines for unstable angina. JAMA 1996;276:1568-74.
16. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
17. Godlee F, editor. Clinical evidence. Issue 3. London: BMJ Publishing Group; 2000.
18. British Cardiac Society Guidelines and Medical Practice Committee & Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. Heart 2001;85:133-42.
19. Department of Health. National service framework for coronary heart disease. London: Department of Health; 2000.
20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
21. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 1998;19:89-98.
22. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
23. National Institute for Clinical Excellence. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (Technology Appraisal No. 12). London: NICE; 2000.
24. FRISC Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:708-15.
25. Unstable Angina Guideline Panel. Unstable angina: diagnosis and management. Clinical practice guideline No. 10 (amended). Report No. 94-0602. Rockville, MD: US Agency for Health Care Policy and Research and the National Heart, Lung and Blood Institute; 1994.
26. NHS Executive Northern and Yorkshire Regional Office. Guidelines for the management of patients with ischaemic heart disease. Leeds: NHSE; 1998.
27. Fischer A, Frankish R, Taylor R. Clinical and cost effectiveness of glycoprotein IIb/IIIa inhibitors in association with percutaneous coronary intervention (PCI). London: National Institute for Clinical Excellence; 2000.
28. Development and Evaluation Committee. Low molecular weight heparins (dalteparin and enoxaparin) compared with unfractionated heparin for unstable angina and non-Q-wave myocardial infarction. Development and Evaluation Committee Report No. 93. Report withdrawn. Southampton: Wessex Institute for Health Research and Development; 1999.
29. Development and Evaluation Committee. Dalteparin and enoxaparin for unstable angina and non-Q-wave myocardial infarction: update. Southampton: Wessex Institute for Health Research and Development; 2000.
30. National Health and Medical Research Council. Clinical practice guidelines: diagnosis and management of unstable angina. Canberra: Australian Government Publishing Service; 1996.
31. National Heart Foundation and Cardiac Society of Australia and New Zealand. Management of unstable angina: guidelines 2000. Med J Aust 2000;173:S64-89.
32. Eccles M, Freemantle N, Mason J, North of England Aspirin Guideline Development Group. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ 1998; 316:1303-9.
33. Braunwald E, Unstable Angina Guideline Panel. Unstable angina: diagnosis and management. Clinical practice guideline. AHCPR Publication. Vol. 10. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute; 1994.
34. Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, et al. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists. Health Technol Assess 2002;6(25):1-160.
35. Boersma E, Harrington R, Moliterno D, White H, Theroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
36. Bosch X, Marrugat J. Platelet glycoprotein IIb/IIIa blockers for percutaneous transluminal coronary angioplasty and unstable angina (Cochrane review). In Cochrane Library (Issue 4) Oxford: Update Software; 2001.
37. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284:1549-58.
38. Brown DL, Fann CSJ, Chang CJ. Effect of glycoprotein IIb/IIIa inhibitors on the individual components of composite endpoints used in clinical trials of unstable angina and non-Q-wave myocardial infarction. Cardiovasc Drugs Ther 2000;14:253-8.
39. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000; 36:381-6.
40. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-11.
41. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
42. Chen YH, Chen JW, Wu TC, Ding PA, Wang SP, Chang MS. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chin Med J 2000;63:8-15.
43. Galassi AR, Russo G, Nicosia A, Tamburino C, Foti R, Rodi G, et al. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome. Cardiologia 1999;44:639-45.
44. Harrington R. Optimal dosing of a platelet glycoprotein IIb/IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes: results from the PARAGON B study. In Proceedings from the American College of Cardiology 49th Annual Scientific Session; 12-15 March 2000, Anaheim, CA, USA. 2000.
45. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis - II. Lancet 1997;349:1422-8.
46. Schulman SP, Goldschmidt Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation 1996;94:2083-9.
47. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. CAPTURE Study Investigators, Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
48. Hasdai D, Holmes DR, Criger DA, Topol EJ, Califf RM, Harrington RA. Age and outcome after acute coronary syndromes without persistent ST-segment elevation. Am Heart J 2000; 139:858-66.
49. Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B troponin T substudy. Circulation 2001; 103:2891-6.
50. Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J 2000; 21:371-81.
51. Dyke CM, Bhatia D, Lorenz TJ, Marso SP, Tardiff BE, Hogeboom C, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000; 70:866-71.
52. Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, et al. PURSUIT Investigators. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using integrilin Therapy (PURSUIT) trial. Circulation 2000; 102:1093-100.
53. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, et al. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. Circulation 2000;102:1101-6.
54. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000; 101:2557-67.
55. Theroux P, Alexander J, Pharand C, Barr E, Snapinn S, Ghannam AF, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000;102:2466-72.
56. Cura FA, Bhatt DL, Lincoff AM, Kapadia SR, L'Allier PL, Ziada KM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 2000;102:28-34.
57. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, et al. EPILOG Trial Investigators. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation 1998; 97:857-64.
58. Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, et al. EPILOG Investigators. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. Circulation 1998; 97:1912-20.
59. Cho L, Marso SP, Bhatt DL, Topol EJ. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial. J Womens Health Gender Med 2000;9:741-6.
60. Lincoff AM. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. Am Heart J 2000;139:S46-52.
61. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation 1999;99:2371-7.
62. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999; 99:2892-900.
63. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999; 354:1757-62.
64. Eli Lilly. Reopro (abciximab) in unstable angina and acute coronary syndromes. Submission to the National Institute for Clinical Excellence; 2000.
65. PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-43.
66. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
67. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
68. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343:881-6.
69. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
70. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285:2468-73.
71. Harrington RA, Kleiman NS, Kottke Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
72. Hanrath P, Vom Dahl J, Paulus O, Heyndrickx G, Sosa JA, Muller D, et al. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
73. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
74. Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999; 99:1951-8.
75. Topol EJ, Lincoff AM, Califf RM, Tcheng JE, Cohen EA, Kleiman NS, et al. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
76. ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999;100:799-806.
77. Blann AD, Lip GY. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res 2001; 101:321-7.
78. Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1997;80:34-8b.
79. Simoons ML. New findings from the PURSUIT study. Eur Heart J Suppl 1999;1:N30-4.
80. Hunink M, Glaziou P, Siegel J, Weeks J, Pliskin J, Elstein A, et al. Decision making in health and medicine. Integrating evidence and values. Cambridge: Cambridge University Press; 2001.
81. Department of Health. Policy appraisal and health. London: Department of Health; 1995.
82. Sculpher MJ, Smith DH, Clayton T, Henderson RA, Buxton MJ, Pocock SJ, et al. Coronary angioplasty versus medical therapy for angina: health service costs based on the second Randomised Intervention Treatment of Angina (RITA-2) trial. Eur Heart J 2002; 23:1291-300.
83. NHS Executive. The new NHS - 2000 reference cost. London: NHS Executive; 2001.
84. Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. The management of dyspepsia: a systematic review. Health Technol Assess 2000;4(39).
85. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary 42. London: British Medical Association; 2001.
86. Boersma R, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
87. Gray D, Keating NA, Murdock J, Skene AM, Hampton JR. Impact of hospital thrombolysis policy on out-of-hospital response to suspected myocardial infarction. Lancet 1993;341:654-7.
88. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994;14:52-8.
89. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17:479-500.
90. Thompson S, van Busschbach J, van Hout B. Measuring health-related quality of life with the EuroQol in patients with angina pectoris after heparin-coated Pamaz-Schartz stent implantation or PTCA. In Greiner W, Graf VD, Schulenburg JM, Piercy J, editors. EuroQol plenary meeting, Hannover, 1998. Hannover: Uni-Verlag Witte; 1998.
91. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-24.
92. Fryback DG, Chinnis JO, Ulviva JW. Bayesian cost-effectiveness analysis: an example using the GUSTO trial. Int J Technol Assess Health Care 2001;17:83-97.
93. Johannesson M, Weinstein S. On the decision rules of cost-effectiveness analysis. Journal of Health Economics 1993; 12:459-67.
94. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-89.
95. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994; 3:309-19.
96. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149-56.
97. Schering-Plough. Eptifibatide in treating acute coronary syndromes in the United Kingdom. Submission to the National Institute for Clinical Excellence; 2000.
98. Mark DB, Harrington RA, Lincolf AM, Califf RM, Nelson CL, Tsiatis AA, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-71.
99. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Making 1998; 18:S68-80.
100. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 1999;18:341-64.
101. Palmer S, Smith P. Incorporating option values into the economic evaluation of health care technologies. Journal of Health Economics 2000; 19:755-66.
102. Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the efficiency and relevance of health technology assessment: the role of decision analytic modelling. Report No. DP 179. York: Centre for Health Economics; 2000.
103. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ 1999;8:269-74.
104. Claxton K, Thompson K. A dynamic programming approach to the efficient design of clinical trials. Journal of Health Economics 2001; 20:797-822.
105. Department of Health. Hospital episode statistics 1995/6. London: OPCS; 1998.
106. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002; 360:711-15.
107. Claxton K, Posnett J. An economic approach to clinical trial design and research priority setting. Health Econ 1996; 5:513-24.
108. National Institute for Clinical Excellence. Full guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. London: NICE; 2002.
109. American College of Cardiology and American Heart Association. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. American College of Cardiology and American Heart Association; 2002. URL: http://www.acc.org/clinical/guidelines/unstable/ update_explantext.htm Accessed 8 April 2002.
110. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996; 94:1291-7.
111. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random effects regression model for meta-analysis. Stat Med 1995; 14:395-411.